NRx Pharmaceuticals (NASDAQ:NRXP) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval